0N6A is currently developing the following drugs: Pembrolizumab, Olaptesed Pegol, Pembrolizumab, Bevacizumab, Temozolomide (Tmz), Radiotherapy, Olaptesed Pegol. These drug candidates are in various stages of clinical development as the company works toward FDA approval.